ZG096

ZG096 is an orally bioavailable small molecule inhibitor of the urate transporter 1 (URAT1), encoded by the SLC22A12 gene. Developed by Suzhou Zelgen Biopharmaceutical in collaboration with academic institutions including Beijing Chao-Yang Hospital and Capital Medical University, ZG096 is designed for the treatment of hyperuricemia and gout. Its mechanism of action involves the selective inhibition of URAT1 in the renal proximal tubules, which prevents the reabsorption of filtered uric acid from the tubular lumen back into the systemic circulation. By promoting uricosuria, ZG096 effectively lowers serum uric acid levels. Clinical development is currently focused on establishing the safety, tolerability, and urate-lowering efficacy of the compound in patients with gouty conditions, positioning it as a potential next-generation uricosuric agent with an improved safety profile compared to older therapies.